Magle Chemoswed Holding AB (publ) (MAGLE.ST)
SEK 33.2
(1.84%)
SEK 33.2
(1.84%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 123.97 Million SEK | 16.86% |
| 2022 | 106.09 Million SEK | 7.83% |
| 2021 | 98.38 Million SEK | 20.06% |
| 2020 | 81.94 Million SEK | -16.91% |
| 2019 | 98.61 Million SEK | -3.19% |
| 2018 | 101.86 Million SEK | -2.89% |
| 2017 | 104.89 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 129.27 Million SEK | 4.27% |
| 2024 Q3 | 370.01 Million SEK | 157.08% |
| 2024 Q2 | 143.92 Million SEK | 11.34% |
| 2023 Q3 | 119.04 Million SEK | 9.65% |
| 2023 Q4 | 123.97 Million SEK | 4.15% |
| 2023 Q1 | 120.15 Million SEK | 13.25% |
| 2023 Q2 | 108.57 Million SEK | -9.64% |
| 2023 FY | 123.97 Million SEK | 16.86% |
| 2022 Q3 | 110.6 Million SEK | 0.3% |
| 2022 Q2 | 110.26 Million SEK | -1.85% |
| 2022 Q1 | 112.35 Million SEK | 14.2% |
| 2022 FY | 106.09 Million SEK | 7.83% |
| 2022 Q4 | 106.09 Million SEK | -4.08% |
| 2021 Q1 | 75.6 Million SEK | -7.73% |
| 2021 FY | 98.38 Million SEK | 20.06% |
| 2021 Q4 | 98.38 Million SEK | 0.48% |
| 2021 Q3 | 97.91 Million SEK | 35.65% |
| 2021 Q2 | 72.18 Million SEK | -4.53% |
| 2020 FY | 81.94 Million SEK | -16.91% |
| 2020 Q3 | 72.95 Million SEK | -8.49% |
| 2020 Q2 | 79.72 Million SEK | -4.57% |
| 2020 Q1 | 83.53 Million SEK | -15.3% |
| 2020 Q4 | 81.94 Million SEK | 12.33% |
| 2019 Q4 | 98.61 Million SEK | 0.0% |
| 2019 FY | 98.61 Million SEK | -3.19% |
| 2019 Q1 | - SEK | 0.0% |
| 2018 FY | 101.86 Million SEK | -2.89% |
| 2017 FY | 104.89 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | -16.308% |
| Ziccum AB (publ) | 6.38 Million SEK | -1840.811% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -5155.574% |
| BioArctic AB (publ) | 139.5 Million SEK | 11.128% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -258.29% |
| Mendus AB (publ) | 51.22 Million SEK | -142.028% |
| Genovis AB (publ.) | 98.04 Million SEK | -26.449% |
| Intervacc AB (publ) | 21.68 Million SEK | -471.859% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -364.202% |
| Active Biotech AB (publ) | 13.4 Million SEK | -825.216% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -669.244% |
| Aptahem AB (publ) | 8.99 Million SEK | -1277.877% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -203.431% |
| Kancera AB (publ) | 17.97 Million SEK | -589.615% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -168.469% |
| Fluicell AB (publ) | 8.91 Million SEK | -1290.679% |
| Saniona AB (publ) | 86.08 Million SEK | -44.023% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -2303.625% |
| Biovica International AB (publ) | 34.76 Million SEK | -256.6% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -962.556% |
| AcouSort AB (publ) | 10.37 Million SEK | -1094.633% |
| Xintela AB (publ) | 14.01 Million SEK | -784.616% |
| Abliva AB (publ) | 16.78 Million SEK | -638.806% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 42.228% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -971.648% |
| OncoZenge AB (publ) | 1.69 Million SEK | -7197.175% |
| Amniotics AB (publ) | 10.54 Million SEK | -1075.491% |
| 2cureX AB (publ) | 2.93 Million SEK | -4124.157% |
| CombiGene AB (publ) | 4.15 Million SEK | -2883.134% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -2701.152% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 92.082% |
| Camurus AB (publ) | 414.81 Million SEK | 70.113% |
| Corline Biomedical AB | 6.78 Million SEK | -1726.175% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | -102.062% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -546.937% |
| I-Tech AB | 16.2 Million SEK | -665.066% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 89.546% |
| Cyxone AB (publ) | 4.69 Million SEK | -2541.223% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -830.215% |
| Biosergen AB | 5.08 Million SEK | -2338.132% |
| Cantargia AB (publ) | 54.97 Million SEK | -125.539% |
| NextCell Pharma AB | 13.68 Million SEK | -805.68% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | -72.553% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -800.253% |
| Nanologica AB (publ) | 79.32 Million SEK | -56.289% |
| SynAct Pharma AB | 51.83 Million SEK | -139.185% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -1459.68% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -2286.532% |
| LIDDS AB (publ) | 3.75 Million SEK | -3200.825% |
| Lipum AB (publ) | 7.53 Million SEK | -1544.72% |
| BioInvent International AB (publ) | 90.45 Million SEK | -37.065% |
| Alzinova AB (publ) | 9.33 Million SEK | -1228.679% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 31.729% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -6810.758% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -570.374% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -3130.302% |
| Simris Alg AB (publ) | 148.93 Million SEK | 16.758% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | -74.329% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 74.287% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -872.842% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -1607.7% |